Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1986; 55(02): 282-291
DOI: 10.1055/s-0038-1661538
DOI: 10.1055/s-0038-1661538
International Committee Communications
ICTH - Subcommittee on Clinical Trials: Registry of Multicenter Clinical Trials
Seventh Report - 1985Further Information
Publication History
Received 24 February 1986
Accepted 25 February 1986
Publication Date:
18 July 2018 (online)

-
References
- 1 Verstraete M. Registry of prospective clinical trials. First report. Thrombos Diathes Haemorrh 1975; 33: 655-663
- 2 Verstraete M. Registry of prospective clinical trials. Second report. Thromb Haemostas 1976; 36: 239-250
- 3 Verstraete M. Registry of prospective clinical trials. Third report. Thromb Haemostas 1978; 39: 759-767
- 4 Verstraete M. Registry of prospective clinical trials. Fourth report. Thromb Haemostas 1980; 43: 176-181
- 5 Verstraete M. Registry of prospective clinical trials. Fifth report. Thromb Haemostas 1982; 48: 334-338
- 6 Verstraete M. Registry of prospective clinical trials. Sixth report. Thromb Haemostas 1984; 51: 283-290
- 7 Leizorovicz A, Boissel JP. Oral Anticoagulant in Patients Surviving Myocardial Infarction: a New Approach for Old Data. Eur J Clin Pharmacol 1983; 24: 333-336
- 8 Rentrop KP et al. Effects of Intracoronary Streptokinase and Intracoronary Nitroglycerin Infusion on Coronary Angiographic Patterns and Mortality in Patients with Acute Myocardial Infarction. N Engl J Med 1985; 311: 1457-1463
- 9 TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phases I findings. N Engl J Med 1985; 312: 932-936
- 10 Verstraete M, Bernard R, Bory M, Brower RW, Collen D, DeBono DP, Erbel R, Huchmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michelsy HR, Rutsch W, Schartl M, Schmidt W, Uebis R, Von Essen R. Randomized Trial of Intravenous Recombinant Tissue-type Plasminogen Activator versus Intravenous Streptokinase in Acute Myocardial Infarction. Lancet 1985; 1: 842-847
- 11 Freiman JA, Chalmers TC, Smith H, Kuebler R. The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Controlled Trial. N Engl J Med 1978; 299: 690-694
- 12 Kennedy JW, Ritchie JL, Davis KB, Stadius ML, Maynard C, Fritz JK. The Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction: a 12-month Follow-up Report. N Engl J Med 1985; 312: 1073-1078
- 13 Chesebro JM et al. A Platelet-Inhibitor-Drug Trial in Coronary Artery By-Pass Operations: Benefit of Perioperative Dipyridamole and Aspirin Therapy on Early Post-Operative Vein-Graft Patency. N Engl J Med 1982; 307: 73-78
- 14 WHO. Cooperative Trial on Primary Prevention of Ischemic Heart Disease Using Clofibrate to Lower Serum Cholesterol: Mortality Follow-Up: Report of the Committee of Principal Investigators. Lancet 1980; 2: 379-385
- 15 The Coronary Drug Project Group. Clofibrate and Niacin in Coronary Heart Disease. JAMA 1975; 231: 360-380
- 16 Hess H, Mietaschk A, Deichsel G. Drug-Induced Inhibition of Platelet Function Delays Progression of Peripheral Occlusive Arterial Disease; a Double-Blind Arteriographically Controlled Trial. Lancet 1985; 1: 415-419
- 17 Bulkley BH, Hutchins GM. Accelerated “A1therosclerosis” a Morphologic Study of 97 Saphenous Vein Coronary Artery Bypass Grafts. Circulation 1977; 55: 163-169
- 18 Campeau L, Enjalbert M, Lesperance J, Bourassa M, Kwiterovitch P, Walcholder S, Sniderman A. The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native Circulation; a Study 10 Years after Aortocoronary Bypass Surgery. N Engl J Med 1984; 311: 1329-1332